Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.40 |
| ▸ | ITGAV | P06756 | 3/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 11/20 | 0.39 |
| ▸ | PPARD | Q03181 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501575 | 1.00 | ITGB3 (0.40) | ITGB3ITGAVITGA2BPPARAPPARD | |
| SCHEMBL6499244 | 0.92 | CNR1 (0.38) | ITGB3ITGAVITGA2BKDM4EHTT | |
| SCHEMBL383252 | 0.89 | CASR (0.42) | ITGB3ITGAVITGA2BKDM4EHTT | |
| SCHEMBL383350 | 0.89 | CASR (0.42) | ITGB3ITGAVITGA2BKDM4EHTT | |
| SCHEMBL6498548 | 0.88 | CCR2 (0.35) | RAB9AKDM4EHTTPDGFRBKDR | |
| SCHEMBL6509189 | 0.87 | KMT2A (0.34) | RAB9AKDM4EHTTPDGFRBKDR | |
| SCHEMBL6504442 | 0.84 | LMNA (0.40) | ITGB3ITGAVITGA2BRAB9A | |
| SCHEMBL7469429 | 0.84 | ITGB3 (0.43) | ITGB3ITGAVITGA2BPPARAPPARD | |
| SCHEMBL7474930 | 0.84 | ITGB3 (0.43) | ITGB3ITGAVITGA2BPPARAPPARD | |
| SCHEMBL383158 | 0.84 | ITGB3 (0.44) | ITGB3ITGAVITGA2BRAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | claimed |
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | ITGB3 2/4885ITGAV 1/4885ITGA2B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.